These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32612180)

  • 1. Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease.
    Peng YL; Tain YL; Lee CT; Yang YH; Huang YB; Wen YH; Hsu CN
    Sci Rep; 2020 Jul; 10(1):10734. PubMed ID: 32612180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
    Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
    Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
    Chou HW; Chiu HT; Tsai CW; Ting IW; Yeh HC; Huang HC; Kuo CC;
    Nephrol Dial Transplant; 2018 Sep; 33(9):1620-1627. PubMed ID: 29165620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
    Lee JW; Lee KH
    Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
    Mitri G; Wittbrodt ET; Turpin RS; Tidwell BA; Schulman KL
    J Manag Care Spec Pharm; 2016 Apr; 22(4):326-36. PubMed ID: 27023686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
    Levy G; Shi JM; Cheetham TC; Rashid N
    Perm J; 2018; 22():17-142. PubMed ID: 30201087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia.
    Zhang X; Wan D; Yang G; Peng Q; Wang X
    Int Urol Nephrol; 2019 Dec; 51(12):2273-2283. PubMed ID: 31646459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia.
    Tsuji T; Ohishi K; Takeda A; Goto D; Sato T; Ohashi N; Fujigaki Y; Kato A; Yasuda H
    Clin Exp Nephrol; 2018 Dec; 22(6):1300-1308. PubMed ID: 29700702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preservation of renal function during gout treatment with febuxostat: a quantitative study.
    Whelton A; MacDonald PA; Chefo S; Gunawardhana L
    Postgrad Med; 2013 Jan; 125(1):106-14. PubMed ID: 23391676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Febuxostat versus Allopurinol on the Glomerular Filtration Rate and Hyperuricemia in Patients with Chronic Kidney Disease.
    Nagaraju SP; Shenoy SV; Rao I; Prabhu RA; Rangaswamy D; Bhojaraja MV; Guddattu V
    Saudi J Kidney Dis Transpl; 2023 Jul; 34(4):279-287. PubMed ID: 38345582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
    Hu AM; Brown JN
    Clin Rheumatol; 2020 Nov; 39(11):3287-3294. PubMed ID: 32418037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease.
    Tsuruta Y; Mochizuki T; Moriyama T; Itabashi M; Takei T; Tsuchiya K; Nitta K
    Clin Rheumatol; 2014 Nov; 33(11):1643-8. PubMed ID: 25048744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression.
    Park S; Lee JP; Kim DK; Kim YS; Lim CS
    PLoS One; 2022; 17(2):e0264627. PubMed ID: 35226683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
    Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC
    Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
    Sezai A; Soma M; Nakata K; Osaka S; Ishii Y; Yaoita H; Hata H; Shiono M
    J Cardiol; 2015 Oct; 66(4):298-303. PubMed ID: 25649025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of efficacy and safety between febuxostat and allopurinol in early post-renal transplant recipients with new onset of hyperuricemia.
    Shen X; Li J; Fu Q; Liu L; Gao X; Chen X; Chen P; Wang C
    J Clin Pharm Ther; 2019 Apr; 44(2):318-326. PubMed ID: 30582178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases
.
    Yang AY
    Int J Clin Pharmacol Ther; 2020 Jan; 58(1):21-28. PubMed ID: 31657714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M; Cimmino MA; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
    Yang N; Cao B
    J Clin Pharm Ther; 2022 Dec; 47(12):2214-2222. PubMed ID: 36403976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.
    Hosoya T; Kimura K; Itoh S; Inaba M; Uchida S; Tomino Y; Makino H; Matsuo S; Yamamoto T; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H
    Trials; 2014 Jan; 15():26. PubMed ID: 24433285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.